Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma

Medical Oncology

Volumn 25, Issue 4, 2008, Pages 437-442

  Kilickap, Saadettin ^a   Yavuz, Bunyamin ^a   Aksoy, Sercan ^a   Sahiner, Levent ^a   Dincer, Murat ^a   Harputluoglu, Hakan ^a   Erman, Mustafa ^a   Aytemir, Kudret ^a   Tokgozoglu, Lale ^a   Barista, Ibrahim ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Cardiotoxicity; Chemotherapy; Echocardiography; Non Hodgkin lymphoma; Rituximab; Tissue Doppler echocardiography

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; DOXORUBICIN; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEART; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PREDNISONE; RISK FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VINCRISTINE;

EID: 58549111027     PISSN: 13570560     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12032-008-9062-2     Document Type: Article

References (30)

1. DG Maloney AJ Grillo-López CA White D Bodkin RJ Schilder JA Neidhart 1997 IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma Blood. 90 2188 95
2. B Coiffier C Haioun N Ketterer A Engert H Tilly D Ma 1998 Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study Blood. 92 1927 32
3. P McLaughlin AJ Grillo-López BK Link R Levy MS Czuczman ME Williams 1998 Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol. 16 2825 33
4. JM Foran AS Rohatiner D Cunningham RA Popescu P Solal-Celigny M Ghielmini 2000 European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma J Clin Oncol. 18 317 24
5. JM Vose BK Link ML Grossbard M Czuczman A Grillo-Lopez P Gilman 2001 Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma J Clin Oncol. 19 389 97
6. B Coiffier E Lepage J Briere R Herbrecht H Tilly R Bouabdallah 2002 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med. 346 235 42
7. DL Keefe 2001 Anthracycline-induced cardiomyopathy Semin Oncol. 28 4 Suppl 12 2 7
8. K Shan AM Lincoff JB Young 1996 Anthracycline-induced cardiotoxicity Ann Intern Med. 125 47 58
9. DD Von Hoff MW Layard P Basa HL Davis Jr AL Von Hoff M Rozencweig 1979 Risk factors for doxorubicin-induced congestive heart failure Ann Intern Med. 91 710 7
10. V Garypidou V Perifanis K Tziomalos S Theodoridou 2004 Cardiac toxicity during rituximab administration Leuk Lymphoma 45 1 203 4
11. S Kilickap I Barista E Akgul K Aytemir S Aksoyek S Aksoy 2005 cTnT can be a useful marker for early detection of anthracycline cardiotoxicity Ann Oncol. 16 5 798 804
12. L Lenaz JA Page 1976 Cardiotoxicity of adriamycin and related anthracyclines Cancer Treat Rev. 3 111 20
13. EA Lefrak J Pitha S Rosenheim JA Gottlieb 1973 A clinicopathologic analysis of adriamycin cardiotoxicity Cancer. 32 302 14
14. MK Ali A Soto D Maroongroge S Bekheit-Saad AU Buzdar GR Blumenschein 1979 Electrocardiographic changes after adriamycin chemotherapy Cancer, 43 465 71
15. JS Steinberg AJ Cohen AG Wasserman P Cohen AM Ross 1987 Acute arrhythmogenicity of doxorubicin administration Cancer. 60 1213 8
16. S Kilickap E Akgul S Aksoy K Aytemir I Barista 2005 Doxorubicin-induced second degree and complete atrioventricular block Europace. 7 3 227 30
17. S Kilickap I Barista E Akgul K Aytemir S Aksoy G Tekuzman 2007 Early and late arrhythmogenic effects of doxorubicin South Med J. 100 3 262 5
18. MS Czuczman AJ Grillo-López CA White M Saleh L Gordon AF LoBuglio 1999 Treatment of patients with low-grade B-cell lymphoma with the combination of chimaeric anti CD-20 monoclonal antibody and CHOP chemotherapy J Clin Oncol. 17 268 76
19. MS Czuczman R Weaver B Alkuzweny J Berlfein AJ Grillo-López 2004 Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up J Clin Oncol. 22 4659 64
20. P Feugier A Van Hoof C Sebban P Solal-Celigny R Bouabdallah C Fermé 2005 Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol. 23 18 4117 26
21. LC Lim LP Koh P Tan 1999 Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia J Clin Oncol. 17 1962 3
22. U Winkler M Jensen O Manzke H Schulz V Diehl A Engert 1999 Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8) Blood. 94 2217 24
23. JC Byrd JK Waselenko TJ Maneatis T Murphy FT Ward BP Monahan 1999 Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusionrelated side effects and rapid blood tumor clearance J Clin Oncol. 17 791 5
24. JA Hernández R Diloy D Salat N del Río X Martínez JM Castellví 2003 Fulminant hepatitis subsequent to reactivation of precore mutant hepatitis B virus in a patient with lymphoma treated with chemotherapy and rituximab Haematologica. 88 22
25. TH Westhoff F Jochimsen A Schmittel M Stoffler-Meilicke JH Schafer W Zidek 2003 Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy Blood. 102 1930
26. BD Cheson JN Frame D Vena N Quashu JM Sorensen 1998 Tumor lysis syndrome: an uncommon complication of fludarabine therapy of chronic lymphatic leukaemia J Clin Oncol. 16 2313 20
27. KR Hande GC Garrow 1993 Acute tumor lysis syndrome in patients with high-grade non-Hodgkin's lymphoma Am J Med. 94 133 9
28. G Lenz M Dreyling E Hoster B Wörmann U Dührsen B Metzner 2005 Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) J Clin Oncol. 23 9 1984 92
29. S Gellrich JM Muche A Wilks KC Jasch C Voit T Fischer 2005 Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas-an applicational observation Br J Dermatol. 153 1 167 73
30. E Kimby 2005 Tolerability and safety of rituximab (MabThera) Cancer Treat Rev. 31 6 456 73